Research and Markets (http://www.researchandmarkets.com/research/f2q3j8/peptic_ulcers)
has announced the addition of Global Markets Direct's new report "Peptic
Ulcers - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Peptic Ulcers - Pipeline Review, H2 2012',
provides an overview of the indication's therapeutic pipeline. This
report provides information on the therapeutic development for Peptic
Ulcers, complete with latest updates, and special features on late-stage
and discontinued projects. It also reviews key players involved in the
therapeutic development for Peptic Ulcers. Peptic Ulcers - Pipeline
Review, Half Year is built using data and information sourced from
Global Markets Direct's proprietary databases, Company/University
websites, SEC filings,investor presentations and featured press
releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on
the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Peptic Ulcers.
- A review of the Peptic Ulcers products under development by companies
and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging
from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and
- Coverage of the Peptic Ulcers pipeline on the basis of route of
administration and molecule type.
- Key discontinued pipeline projects.
Takeda Pharmaceutical Company Limited
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
PLx Pharma Inc.
aRigen Pharmaceuticals, Inc.
Logical Therapeutics, Inc.
China Medical System Holdings Limited
Medigreen Biotechnology Corporation
For more information visit http://www.researchandmarkets.com/research/f2q3j8/peptic_ulcers.
Source: Global Markets Direct
[ Back To NFVZone's Homepage ]